| |
|
A021101
|
---
|
NEOADJUVANT FOLFIRINOX AND CHEMORADIATION FOLLOWED BY DEFINITIVE SURGERY AND POSTOPERATIVE GEMCITABINE FOR PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA: AN INTERGROUP SINGLE-ARM PILOT STUDY -- Closed(1/5/2015)
|
| |
|
A021302
|
---
|
IMPACT OF EARLY FDG-PET DIRECTED INTERVENTION ON PREOPERATIVE THERAPY FOR LOCALLY ADVANCED GASTICR
CANCER: A RANDOM ASSIGNMENT PHASE II STUDY --Closed(6/1/2017)
|
| |
| |
|
A071102 |
---
|
A PHASE II/III RANDOMIZED TRIAL OF VELIPARIB OR PLACEBO IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMAWITH MGMT PROMOTER HYPERMETHYLATION - Closed to Accrual (10/15/18)
|
| |
| |
|
A071801 |
---
|
PHASE III TRIAL OF POST-SURGICAL SINGLE FRACTION STEREOTACTIC RADIOSURGERY (SRS) COMPARED WITH FRACTIONATED SRS (FSRS) FOR RESECTED METASTATIC BRAIN DISEASE
Closed on 09/09/2022
|
|
A021501
|
---
|
PREOPERATIVE EXTENDED CHEMOTHERAPY VS. CHEMOTHERAPY PLUS HYPOFRACTIONATED RADIATION THERAPY FOR BORDERLINE RESECTABLE ADENOCARCINOMA OF THE HEAD OF THE PANCREAS
Closed to Accrual Date: 05/06/19
|
| |
|
A091605 |
---
|
A RANDOMIZED PHASE II STUDY OF ANTI-PD1 ANTIBODY [MK-3475 (PEMBROLIZUMAB)] ALONE VERSUS ANTI-PD1 ANTIBODY PLUS STEREOTACTIC BODY RADIATION THERAPY IN ADVANCED MERKEL CELL CARCINOMA-Closed to accrual Date 12/20/2019
|